Patent ID: 7396545

Claim:
A preparation for the treatment of cardiovascular and cerebrovascular diseases, characterized in that it comprises two components both having a quasi-molecular ion mass peak m/z of 537[M-H] − , a second fragment ion m/z of 493[M-H-CO 2 ] − and 295[M-CO 2 -R-H 2 O] − , and a third fragment ion m/z of 159 and 109, with the maximum absorption wave length of 327 nm, wherein the mass spectrum analysis is carried out as follows: (1) HPLC-MS is carried out through the negative ion detection under following conditions of dry gas flow rate: 10 L/min; nebulizer pressure: 60 psi; dry gas temperature: 350° C.; capillary voltage: 3500 v; and m/z scan range: 100-1200; and (2) HPLC-MS n is carried out through the negative ion detection under following conditions of dry gas flow rate: 10 L/min; nebulizer pressure: 60 psi; dry gas temperature: 350° C.; capillary voltage: 3500 v; m/z scan range: 100-800; and fragment amplitude: 1.5-3.0 v.